A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

Researchers at the University of Copenhagen have identified a promising new drug target for weight loss which could revolutionise treatment for millions of people with obesity and type 2 diabetes. The ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

In recent years, interest in these medications—initially developed to treat type 2 diabetes—has exploded, primarily because ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Novo Nordisk is working on a new obesity ... past few months as investors fret that demand for weight-loss drugs isn’t as ...